Sangamo Therapeutics, Inc.
General ticker "SGMO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $128.1M (TTM average)
Sangamo Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -11.7%.
Estimated limits based on current volatility of 19.8%: low 0.10$, high 0.15$
Factors to consider:
- Earnings expected soon, date: 2026-05-11 amc
- Total employees count: 183 (-54.8%) as of 2024
- Top business risk factors: Regulatory and compliance, Financing risks, Manufacturing risks, Supply chain disruptions, Cybersecurity threats
- Current price 56.4% below estimated low
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [0.31$, 0.85$]
- 2026-12-31 to 2027-12-31 estimated range: [0.33$, 0.88$]
Financial Metrics affecting the SGMO estimates:
- Positive: with PPE of -1.0 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -80.11 <= 0.07
- Positive: Investing cash flow per share per price, % of -0.08 > -0.65
- Positive: Interest expense per share per price, % of 0 <= 0.01
Short-term SGMO quotes
Long-term SGMO plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $176.23MM | $57.80MM | $39.55MM |
| Operating Expenses | $450.24MM | $161.77MM | $147.56MM |
| Operating Income | $-274.00MM | $-103.97MM | $-108.00MM |
| Non-Operating Income | $11.10MM | $5.86MM | $-15.50MM |
| R&D Expense | $234.06MM | $111.52MM | $112.67MM |
| Income(Loss) | $-262.90MM | $-98.11MM | $-123.50MM |
| Taxes | $-5.07MM | $-0.17MM | $-0.57MM |
| Profit(Loss)* | $-257.83MM | $-97.94MM | $-122.93MM |
| Stockholders Equity | $82.89MM | $22.77MM | $-14.27MM |
| Assets | $165.32MM | $101.64MM | $59.74MM |
| Operating Cash Flow | $-224.84MM | $-67.14MM | $-97.21MM |
| Capital expenditure | $21.16MM | $0.27MM | $0.10MM |
| Investing Cash Flow | $153.53MM | $37.52MM | $-0.10MM |
| Financing Cash Flow | $14.59MM | $28.38MM | $70.75MM |
| Earnings Per Share** | $-1.48 | $-0.49 | $-0.44 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.